Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
ACADIA Pharmaceuticals Inc. clinical trials
The registry lists 42 studies whose lead sponsor is ACADIA Pharmaceuticals Inc. or one of 1 company grouped under it. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Keep track of what changes. Save the ACADIA Pharmaceuticals Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to ACADIA Pharmaceuticals Inc..
Focus areas
Conditions ACADIA Pharmaceuticals Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 42 of 42.
- ACP-204 in Adults With Alzheimer's Disease PsychosisRecruitingNCT06159673Phase 2/3
- ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant ResponseRecruitingNCT07284667Phase 2
- Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia PsychosisRecruitingNCT07095465Phase 3
- Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia PsychosisRecruitingNCT07029581Phase 2
- ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension StudyEnrolling by invitationNCT06194799Phase 3
- Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromeCompletedNCT06173531Phase 3
- OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromeTerminatedNCT06420297Phase 3
- Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum DisorderTerminatedNCT05555615Phase 2/3
- Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaTerminatedNCT03121586Phase 3
- Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum DisorderCompletedNCT05523895Phase 2/3
- Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of SchizophreniaCompletedNCT04531982Phase 3
- ACP-104 in Acutely Psychotic Subjects With SchizophreniaCompletedNCT00490516Phase 2
- Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease PsychosisCompletedNCT04292223Phase 4
- Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the KneeTerminatedNCT05008835Phase 2
- A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseCompletedNCT03575052Phase 3
- Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseCompletedNCT03623321Phase 3
- Open-Label Extension Study of Trofinetide for Rett SyndromeTerminatedNCT04776746Phase 3
- An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett SyndromeTerminatedNCT04988867Phase 2/3
- Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett SyndromeCompletedNCT04279314Phase 3
- Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)CompletedNCT04181723Phase 3
- Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following BunionectomyCompletedNCT04855240Phase 2
- Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi SyndromeCompletedNCT03649477Phase 3
Sponsor listed in the registry: Levo Therapeutics, Inc. · First submitted before Levo Therapeutics, Inc. became part of ACADIA Pharmaceuticals Inc.
- Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentTerminatedNCT04000009Phase 3
- Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentCompletedNCT03968159Phase 3
- Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose QuetiapineTerminatedNCT04164758Phase 2
- The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) StudyTerminatedNCT03152292
- Relapse Prevention Study of Pimavanserin in Dementia-related PsychosisCompletedNCT03325556Phase 3
- Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)CompletedNCT02970305Phase 2
- An Open-label Safety Study of Pimavanserin in Parkinson's Disease PatientsCompletedNCT01518309Phase 2
- Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and DepressionCompletedNCT03482882Phase 2
- Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)CompletedNCT02970292Phase 3
- A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's DiseaseCompletedNCT03118947Phase 2
- Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)CompletedNCT03018340Phase 2
- A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease PsychosisCompletedNCT00550238Phase 3
- Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)TerminatedNCT02992132Phase 2
- A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease PsychosisCompletedNCT02035553Phase 2
- A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease PsychosisCompletedNCT00658567Phase 3
- A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease PsychosisCompletedNCT00477672Phase 3
- Expanded Access of Pimavanserin for Patients With PD PsychosisApproved for marketingNCT02762591
- A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease PsychosisCompletedNCT01174004Phase 3
- Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and RisperidoneCompletedNCT00361166Phase 2
- Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational DrugCompletedNCT00087542Phase 2